Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer

PRESS RELEASE

LAVAL, Quebec

,

June 11, 2015

/PRNewswire/ --

Valeant Pharmaceuticals International, Inc.

(NYSE: VRX) (TSX: VRX) announced today that

Robert L. Rosiello

was appointed as Executive Vice President and will take over the role of Chief Financial Officer from

Howard Schiller

on

July 1

, 2015. Mr. Schiller will remain on Valeant's Board and is expected to serve as a consultant to Valeant.

"The Board of Directors and I are delighted that Rob has agreed to join Valeant," said

J. Michael Pearson

, Chairman and Chief Executive Officer. "Rob is someone I have worked closely with for 20 years. I know his tremendous expertise in healthcare and in particular M&A, his unquestioned intellect, and work ethic and integrity will prove to be of great value to the Valeant organization and its shareholders. I want to thank Howard for his strong leadership to both myself and the entire organization these past few years and I will continue to rely on his valuable counsel as a member of our Board of Directors."

Mr. Rosiello worked 30 years at

McKinsey & Company

helping healthcare, technology and consumer companies deliver growth through M&A and business unit financial performance improvement. As Senior Partner in charge of the global merger practice for the past decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S.,

Europe

and

Asia

.

Mr. Rosiello serves on the Board of

Catholic Charities of New York

, the

Pew Research Center

and the

Central Selection Committee

of the

Morehead Cain Foundation

. He received his BA in economics from the

University of North Carolina

, where he was a Morehead Scholar. He also earned an MS from the

London School of Economics

and an MBA from

Harvard

.